Suggested remit: To appraise the clinical and cost effectiveness of Odevixibat (A 4250) within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
Status Proposed
Process TAG
ID number 1570

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
11 September 2020 (14:00) Scoping workshop
15 July 2020 - 12 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance